Close Menu

This article has been updated from a previous version to include information about Japanese reimbursement for Invivoscribe's assay.

NEW YORK (GenomeWeb) – The US Food and Drug Administration said on Wednesday that it has approved an expanded indication for Invivoscribe Technologies' LeukoStrat CDx FLT3 Mutation Assay.

Specifically, FDA expanded approval for LeukoStrat for use with Xospata (gilteritinib), an Astellas Pharma drug for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.